Patients in England suffering from a specific form of incurable breast cancer can now breathe a sigh of relief as they gain access to the life-extending drug, Enhertu, through the NHS. This momentous change comes two years after the drug was initially deemed too costly by health authorities. With Enhertu, patients can expect to gain nearly seven additional months of life on average, and some even manage to survive for up to three years longer.
While women in Scotland have been able to access this vital drug since 2023, patients in England have had to wait. The drug is also available in 26 other European nations. Charities and patient advocates have been tirelessly campaigning for broader access since 2024 when the National Institute for Health and Care Excellence (NICE) concluded that Enhertu was not a good value for the money. However, from Thursday onwards, doctors in England are now empowered to prescribe it, and Wales is expected to follow suit soon.
The impact of this decision is significant, with around 1,000 women diagnosed with HER2-low breast cancer expected to benefit each year. Claire Rowney, the chief executive of the charity Breast Cancer Now, expressed her gratitude, stating, “Today we can finally say we did it.” But she also highlighted the bittersweet nature of the announcement, stressing that there are still many friends and loved ones who will not have the opportunity to benefit from this treatment in time.
Kate Wills, a 51-year-old mother who has HER2-low metastatic breast cancer, knows all too well about this emotional rollercoaster. The disease has spread to her bones and lungs, yet one would never guess she is terminally ill. With a demanding job and a family, her social media reflects a vibrant life, although the occasional medical appointment serves as a reminder of her struggle. “I really can’t believe it. I’m so relieved, I’m overjoyed,” she shares, her voice filled with emotion.
Kate’s children, teenagers and in their early 20s, have been her motivation to keep fighting. “I’ve been aiming to stay alive long enough for my youngest to finish school,” she says, her eyes glistening with tears of joy and sorrow. For her, this news is a double-edged sword; while she feels elated, she can’t help but think of those who were not able to access the drug in time. The thought of not being able to witness her children fall in love or get married has haunted her.
The approval of Enhertu has been a much-needed victory, but Kate and many others are also left feeling frustrated over the delays. “I’m thrilled but also angry at how long it’s taken and how rejected we felt,” she admits. These changes have come about in part due to persistent patient campaigns advocating for Enhertu and other similar drugs, which have undoubtedly shifted the balance in favor of access.
Daiichi Sankyo and AstraZeneca, the manufacturers of Enhertu, have welcomed NICE’s decision but emphasize the need for strong collaboration throughout the healthcare system to ensure that patients can reap the benefits effectively. Helen Knight, director of medicines evaluation at NICE, acknowledged the importance of a “commercial solution” but also lamented that this decision may have come too late for many families who have already suffered.
As Kate reflects on her journey, the painful thought of dying unnecessarily weighs heavily on her heart. The fight for access to essential medications continues, and many are left wondering how many more lives could have been saved if these treatments had been available sooner.
Kaynak: Orijinal Haber